Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Chorus Ltd
NZX:CNU
|
NZ |
|
I
|
Icon Group Ltd
TASE:ICON
|
IL |
|
Trainline PLC
LSE:TRN
|
UK |
|
L
|
Lingsen Precision Industries Ltd
TWSE:2369
|
TW |
|
M
|
Mecaro Co Ltd
KOSDAQ:241770
|
KR |
|
F
|
Ferrocarril del Pacifico SA
SGO:FEPASA
|
CL |
|
Duni AB
STO:DUNI
|
SE |
|
D
|
Decora SA
WSE:DCR
|
PL |
|
Raiznext Corp
TSE:6379
|
JP |
|
K
|
Kaleseramik Canakkale Kalebodur Seramik Sanayi AS
IST:KLSER.E
|
TR |
Molecular Partners AG
Total Current Assets
Molecular Partners AG
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Total Current Assets
CHf96.9m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Current Assets
$2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
29%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Current Assets
CHf251.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-4%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Current Assets
CHf223.8m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Current Assets
CHf60.7m
|
CAGR 3-Years
24%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Current Assets
CHf15.2m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Total Current Assets?
Total Current Assets
96.9m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Total Current Assets amounts to 96.9m CHF.
What is Molecular Partners AG's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
-11%
Over the last year, the Total Current Assets growth was -37%. The average annual Total Current Assets growth rates for Molecular Partners AG have been -28% over the past three years , -11% over the past five years .
